 Glycosides
"Glycosides" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Any compound that contains a constituent sugar, in which the hydroxyl group attached to the first carbon is substituted by an alcoholic, phenolic, or other group. They are named specifically for the sugar contained, such as glucoside (glucose), pentoside (pentose), fructoside (fructose), etc. Upon hydrolysis, a sugar and nonsugar component (aglycone) are formed. (From Dorland, 28th ed; From Miall's Dictionary of Chemistry, 5th ed)
| Descriptor ID |
D006027
|
| MeSH Number(s) |
D09.408
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Glycosides".
Below are MeSH descriptors whose meaning is more specific than "Glycosides".
This graph shows the total number of publications written about "Glycosides" by people in this website by year, and whether "Glycosides" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 2005 | 1 | 1 | 2 | | 2009 | 1 | 0 | 1 | | 2010 | 0 | 1 | 1 | | 2013 | 1 | 2 | 3 | | 2014 | 1 | 0 | 1 | | 2015 | 1 | 0 | 1 | | 2016 | 1 | 1 | 2 | | 2017 | 1 | 1 | 2 | | 2018 | 3 | 3 | 6 | | 2019 | 3 | 1 | 4 | | 2020 | 2 | 0 | 2 | | 2021 | 3 | 0 | 3 | | 2023 | 0 | 2 | 2 | | 2024 | 4 | 0 | 4 | | 2025 | 1 | 0 | 1 |
To return to the timeline, click here.
Below are the most recent publications written about "Glycosides" by people in Profiles.
-
Aggarwal R, Bhatt DL, Szarek M, Cannon CP, Leiter LA, Inzucchi SE, Lopes RD, McGuire DK, Lewis JB, Riddle MC, Davies MJ, Banks P, Carroll AK, Scirica BM, Ray KK, Kosiborod MN, Cherney DZI, Udell JA, Verma S, Mason RP, Pitt B, Steg PG. Effect of sotagliflozin on major adverse cardiovascular events: a prespecified secondary analysis of the SCORED randomised trial. Lancet Diabetes Endocrinol. 2025 04; 13(4):321-332.
-
Bhatt AS, Bhatt DL, Steg PG, Szarek M, Cannon CP, Leiter LA, McGuire DK, Lewis JB, Riddle MC, Voors AA, Metra M, Lund LH, Testani JM, Wilcox CS, Davies M, Pitt B, Kosiborod MN. Effects of Sotagliflozin on Health Status in Patients With Worsening Heart?Failure: Results From SOLOIST-WHF. J Am Coll Cardiol. 2024 Sep 17; 84(12):1078-1088.
-
Boeder S, Davies MJ, McGill JB, Pratley R, Girard M, Banks P, Pettus J, Garg S. Beta-Hydroxybutyrate Levels and Risk of Diabetic Ketoacidosis in Adults with Type 1 Diabetes Treated with Sotagliflozin. Diabetes Technol Ther. 2024 Sep; 26(9):618-625.
-
Aggarwal R, Bhatt DL, Szarek M, Leiter LA, Cannon CP, Lopes RD, Davies MJ, Banks P, Pitt B, Steg PG. Time to clinical benefit with sotagliflozin in patients with type 2 diabetes and chronic kidney disease: Insights from the SCORED randomized trial. Eur J Heart Fail. 2024 Apr; 26(4):1093-1095.
-
Sridhar VS, Bhatt DL, Odutayo A, Szarek M, Davies MJ, Banks P, Pitt B, Steg PG, Cherney DZI. Sotagliflozin and Kidney Outcomes, Kidney Function, and Albuminuria in Type 2 Diabetes and CKD: A Secondary Analysis of the SCORED Trial. Clin J Am Soc Nephrol. 2024 May 01; 19(5):557-564.
-
Sridhar VS, Heerspink HJL, Davies MJ, Banks P, Girard M, Garg SK, Cherney DZI. The Effects of Sotagliflozin in Type 1 Diabetes on Clinical Markers Associated With Cardiorenal Protection: An Exploratory Analysis of inTandem3. Diabetes Care. 2023 07 01; 46(7):e133-e135.
-
Verma S, Bhatt DL, Dhingra NK, Steg PG, Szarek M, Davies M, Metra M, Lund LH, Pitt B. Time to Benefit With Sotagliflozin in Patients With Worsening Heart?Failure. J Am Coll Cardiol. 2023 04 18; 81(15):1546-1549.
-
Szarek M, Bhatt DL, Steg PG, Cannon CP, Leiter LA, McGuire DK, Lewis JB, Riddle MC, Voors AA, Metra M, Lund LH, Komajda M, Testani JM, Wilcox CS, Ponikowski P, Lopes RD, Banks P, Tesfaye E, Ezekowitz JA, Verma S, Pitt B. Effect of Sotagliflozin on Total Hospitalizations in Patients With Type 2 Diabetes and Worsening Heart Failure : A Randomized Trial. Ann Intern Med. 2021 08; 174(8):1065-1072.
-
Bode BW, Cengiz E, Wadwa RP, Banks P, Danne T, Kushner JA, McGuire DK, Peters AL, Strumph P, Sawhney S. Effects of Sotagliflozin Combined with Intensive Insulin Therapy in Young Adults with Poorly Controlled Type 1 Diabetes: The JDRF Sotagliflozin Study. Diabetes Technol Ther. 2021 01; 23(1):59-69.
-
Rodbard HW, Giaccari A, Cariou B, Garg S, Davies MJ, Seth K, Sawhney S. Effect of sotagliflozin as an adjunct to insulin therapy on blood pressure and arterial stiffness in adults with type 1 diabetes: A post hoc pooled analysis of inTandem1 and inTandem2. Diab Vasc Dis Res. 2021 Jan-Feb; 18(1):1479164121995928.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|